Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat. (Q43414816)

23 November 2017

Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat. (English)

1 reference

23 November 2017

1 reference

Pseudomonas aeruginosa

1 reference

5

1 reference

23 November 2017

Margaret L Dunkley

1

1 reference

23 November 2017

Sonal Rajyaguru

series ordinal

2

1 reference

23 November 2017

Amanda McCue

series ordinal

3

1 reference

23 November 2017

Allan W Cripps

series ordinal

4

1 reference

23 November 2017

1 October 2003

1 reference

FEMS Immunology and Medical Microbiology

23 November 2017

1 reference

23 November 2017

39

1 reference

23 November 2017

1

1 reference

23 November 2017

37-44

1 reference

The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

An important role for intestinally derived T cells in respiratory defence

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Purification of immunoglobulin g (IgG)

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900176-7

7 January 2021

10.1016/S0928-8244(03)00176-7

Identifiers

DOI

1 reference

23 November 2017

1 reference